MFC Syngeneic Model Service for Gastric Cancer

The MFC syngeneic model is the most widely used immunocompetent platform for gastric cancer research, engrafting an MNNG-induced forestomach carcinoma line into syngeneic 615 inbred hosts with reproducible growth and a documented propensity for spontaneous lung metastasis. Alfa Cytology delivers this benchmark model as a complete preclinical service — authenticated cell banking, subcutaneous or orthotopic gastric-wall implantation, metastatic and immunotherapy study formats, scheduled monitoring, and full histopathology — giving sponsors a rigorously characterized gastric cancer system with the strain-specific husbandry expertise that few Western providers maintain.

Overview of MFC Syngeneic Model for Gastric Cancer

MFC holds the distinction of being the most widely used murine gastric cancer cell line in existence, and it carries a distinctly Chinese pedigree: it was established in 1987 by Qian and colleagues at the Chinese Academy of Medical Sciences from a forestomach carcinoma that arose in 615 inbred mice treated with N-methyl-N′-nitro-N-nitrosoguanidine (MNNG), with the original report noting the line's striking capacity for spontaneous hematogenous metastasis. The 615 strain — an inbred line developed in China with partial C57BL/6 ancestry but a distinct haplotype — is non-negotiable for this model: MFC is genuinely syngeneic only in 615 hosts, whereas implantation into C57BL/6J mice provokes immune rejection with characteristic two-week growth followed by spontaneous regression, a documented pitfall for laboratories that default to standard strains. Because the murine forestomach is lined by squamous epithelium, MFC faithfully models the squamous carcinoma phenotype of the forestomach — a nuance that makes it a workhorse for gastric tumor immunology even as it behaves biologically like the squamous cancers of the gastroesophageal region.

Fig 1. Clinical-genomic rationale for TRIM6 targeting validated in the MFC syngeneic gastric cancer model — WGCNA module-trait heatmap, MSS versus MSI expression in TCGA/ACRG cohorts, TRIM6-MLH1 correlation, methylation differences, activated CD8+ T cell correlations, and survival analysis stratified by TRIM6 expression. (Niu, Yinan, et al., 2025)

The model's modern reputation rests on a remarkable run of immunology breakthroughs published in the last several years. It was in MFC-bearing 615 mice that researchers demonstrated that gastric cancer cells, through SLC6A6-mediated competitive uptake of taurine, exhaust CD8⁺ T cells via ER stress and ATF4-driven checkpoint upregulation — a mechanism reported in Cell in 2024. MFC likewise carried the DKK1 story, in which tumor-derived DKK1 programs immunosuppressive macrophages that actively impede anti-PD-1 therapy, and more recent work identified BFAR as a driver of neutrophil infiltration and immunosuppressive reprogramming through the PRP19–YBX1 axis. Standard deployment is straightforward and fast: subcutaneous inoculation of 10⁶ cells into 615 flanks produces robust tumors, while orthotopic gastric-wall injection into the stomach serosa recreates primary gastric lesions with greater biological significance, and luciferase-tagged MFC derivatives enable quantitative bioluminescence tracking of primary growth and lung dissemination. Reviewers of gastric cancer models note two honest caveats — graft tumors of this class induce an unnaturally hyperinflammatory state after transplantation, and true C57BL/6-background gastric adenocarcinoma lines remain an unmet need — both of which argue for experienced, strain-disciplined execution. For sponsors, MFC offers what few platforms can: a near-forty-year publication record, contemporary high-impact immunology, and a genuinely metastatic immunocompetent gastric phenotype.

Cell Line Information: MFC

MFC is a murine forestomach carcinoma line established in 1987 (Zhonghua Zhong Liu Za Zhi 9:261–264) at the Chinese Academy of Medical Sciences from an MNNG-treated 615 inbred mouse, and it is distributed by Chinese repositories and international cell banks alike. Luciferase- and fluorescent-protein-tagged MFC derivatives are commercially available for optical tracking studies. Core characteristics are compiled below.

Our Services

Engaging Alfa Cytology for the MFC syngeneic model consolidates a complete, IACUC-compliant program under one accountable team: authenticated, low-passage MFC or reporter-tagged banks are maintained with mycoplasma-free certification, 615-strain hosts are sourced from validated breeders and acclimated — never substituted with C57BL/6 — tumors are established subcutaneously or orthotopically in the gastric wall at documented efficiencies, and treatment arms from checkpoint inhibitors to natural-product pharmacology run through scheduled imaging to terminal gastric and lung histopathology, all returned as an audit-ready data package.

Workflow of MFC Syngeneic Model Construction

MFC studies stand or fall on one discipline no other murine gastric line demands: absolute strain fidelity to the 615 background. Around that core, the workflow follows the model's well-documented subcutaneous and orthotopic formats.

1. Cell preparation and quality control: MFC cells (or MFC-Luc derivatives) are expanded at low passage, confirmed mycoplasma-free, and luciferase activity validated in vitro; suspensions are prepared fresh at 10⁶ cells per inoculum.
2. Host selection and acclimation: 615 inbred mice, male or female and typically 6–8 weeks of age, are sourced from validated breeders, quarantined, and acclimated in a specific-pathogen-free barrier facility — C57BL/6 substitution is expressly avoided given the documented rejection-and-regression pitfall.
3. Implantation: subcutaneous route. Cells in 0.1 mL PBS are injected into the flank; the site is compressed briefly on needle withdrawal, and palpable tumors typically establish within the first week.
4. Implantation: orthotopic gastric-wall route. Under isoflurane anesthesia, a midline laparotomy exposes the stomach, and 10⁶ cells in a small volume are injected into the gastric wall serosa with a fine needle; the stomach is returned to the abdomen and the incision closed in layers.
5. Closure and postoperative care: Analgesia is administered, and mice recover with daily monitoring of weight, activity, and incision integrity against predefined humane endpoints.
6. Randomization and treatment. Mice are randomized by tumor volume or imaging signal into arms, and test articles: checkpoint inhibitors, taurine-pathway or macrophage-targeting agents, natural-product formulations, or combination regimens — are dosed per protocol.
7. Longitudinal monitoring: Flank tumors are measured by caliper on the protocol cadence; luciferase-tagged cohorts undergo bioluminescence imaging after intraperitoneal D-luciferin injection to track primary growth, and lungs are screened for metastatic signal.
8. Endpoint analysis and reporting: At termination, primary tumors and lungs are resected and weighed; tissues undergo H&E with gastric and pulmonary histology, immunohistochemistry (CD8, F4/80, Ly6G, FoxP3, PD-L1 panels), flow-cytometric tumor-infiltrating-leukocyte profiling where specified, and metastatic nodule enumeration, with all data consolidated into the final report.

Fig 2. MFC Syngeneic Model construction workflow.

Case Study-MFC Syngeneic Model Development

Alfa Cytology has applied the MFC syngeneic platform to preclinical programs spanning checkpoint inhibitor evaluation, tumor-immune mechanism studies, natural-product and traditional-medicine pharmacology, and metastasis-focused designs in gastric cancer. In these engagements, caliper and bioluminescence readouts tracked primary tumor kinetics and lung dissemination, while terminal gastric and pulmonary histopathology with immune-marker panels completed the pharmacological and immunological assessment. Study parameters — implantation route, strain logistics, monitoring cadence, and endpoint panels — are tailored to each program. Case materials can be shared under confidentiality agreements upon request.

Why Choose Alfa Cytology?

MFC is a model of beautiful traps: the wrong strain, an uninformed orthotopic attempt, or a hyperinflammatory misread quietly corrupts the study. Alfa Cytology fields the strain-specific husbandry, gastric microsurgery, and immunological literacy this line demands, making the MFC / MFC-Luc syngeneic model a dependable backbone for your gastric cancer program.

• Documented 615-strain discipline, with validated breeder sourcing and zero C57BL/6 substitution risk.
• Both validated formats — robust subcutaneous screening and orthotopic gastric-wall modeling.
• Spontaneous lung metastasis capability, supporting anti-metastatic study designs.
• Contemporary immunology literacy, fluent in the SLC6A6, DKK1, and BFAR mechanisms defined in this line.
• Reporter-line expertise, with MFC-Luc quantitative imaging on IVIS-class systems.
• Honest caveats applied by design, from hyperinflammatory graft states to forestomach squamous biology.
• IACUC-compliant, documentation-rich operations delivering audit-ready records throughout the study.

Contact Us

If your gastric cancer program needs the field's most published murine platform with strain expertise to match, contact us today to discuss MFC / MFC-Luc study design, implantation format, and endpoint strategy with our scientific team. Reach out for a confidential consultation and project quotation — Alfa Cytology looks forward to advancing your next preclinical study.

For research use only. Not intended for any clinical use.